Catalent Price Target Maintained With a $63.50/Share by RBC Capital
Catalent Price Target Maintained With a $63.50/Share by RBC
RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target
RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.
RBC Capital Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $63.5
RBC Capital analyst Sean Dodge maintains $Catalent(CTLT.US)$ with a hold rating, and maintains the target price at $63.5.According to TipRanks data, the analyst has a success rate of 39.3% and a
Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)
Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC
(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.
Unusual Options Activity: CTLT, STX and Others Attract Market Bets, CTLT V/OI Ratio Reaches 250.0
EST Jul 1st Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.O
Catalent Is Maintained at Equal-Weight by Barclays
Catalent Is Maintained at Equal-Weight by Barclays
Catalent Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 11.99% Barclays $47 → $63 Maintains Equal-Weight 04/04/2024 12.88% Stephens & Co. → $63.5 Reite
Express News | Catalent : Barclays Raises Target Price to $63 From $47
Barclays Maintains Catalent(CTLT.US) With Hold Rating, Raises Target Price to $63
Barclays analyst Luke Sergott maintains $Catalent(CTLT.US)$ with a hold rating, and adjusts the target price from $47 to $63.According to TipRanks data, the analyst has a success rate of 39.9% and a t
Barclays Adjusts Catalent Price Target to $63 From $47
Catalent (CTLT) has an average rating of Hold and price targets ranging from $63 to $63.50, according to analysts polled by Capital IQ. Price: 56.57, Change: +0.41, Percent Change: +0.73
Sarepta Cut to Neutral at Citi on Risks to Valuation
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves.
Catalent Gains After Sarepta's Elevidys Gets Label Expansion
Pharmaceutical Contract Manufacturing Market Report 2024-2030: Trends, Opportunities and Competitive Analysis Featuring Thermo Fisher Scientific, Catalent, Lonza, Almac Group, and Recipharm
Express News | Shares of Contract Drug Manufacturer Catalent up 3.3% After FDA's Expanded Use Nod for Sarepta's Duchenne Gene Therapy
Japan Contract Development Manufacturing Organization Market Report 2024-2030, Featuring Lonza, Recipharm, LabCorp, Catalent, WuXi AppTec, CordenPharma, Cambrex, Bushu Pharmaceuticals and Nipro
Trending Stocks Today: Psyence Biomedical Gets a 12.01% Boost Post-Market
June 20th - US stocks trending post-market.Gainers: $Psyence Biomedical(PBM.US)$ rises 12.01% to $0.67 with a turnover of $7.59 million. $Sarepta Therapeutics(SRPT.US)$ surges 32.91% to $164.15 with a
Barclays Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $47
Barclays analyst Luke Sergott maintains $Catalent(CTLT.US)$ with a hold rating, and maintains the target price at $47.According to TipRanks data, the analyst has a success rate of 42.3% and a total av
Ardena Appoints Jeremie Trochu as Chief Executive Officer
Ardena (the "Company") today announces the retirement of Harry Christiaens, PhD and the subsequent appointment of Jeremie Trochu as Chief Executive...